Quest Diagnostics Incorporated (NYSE:DGX – Get Free Report) announced a quarterly dividend on Wednesday, August 14th, RTT News reports. Shareholders of record on Friday, October 4th will be paid a dividend of 0.75 per share by the medical research company on Monday, October 21st. This represents a $3.00 dividend on an annualized basis and a yield of 2.00%.
Quest Diagnostics has increased its dividend by an average of 8.1% annually over the last three years and has raised its dividend every year for the last 13 years. Quest Diagnostics has a payout ratio of 31.3% indicating that its dividend is sufficiently covered by earnings. Analysts expect Quest Diagnostics to earn $9.57 per share next year, which means the company should continue to be able to cover its $3.00 annual dividend with an expected future payout ratio of 31.3%.
Quest Diagnostics Trading Down 0.6 %
NYSE:DGX traded down $0.93 during trading hours on Wednesday, hitting $149.84. 510,355 shares of the stock were exchanged, compared to its average volume of 990,226. The company’s 50 day moving average is $142.54 and its two-hundred day moving average is $135.64. The company has a market capitalization of $16.65 billion, a P/E ratio of 20.17, a price-to-earnings-growth ratio of 2.69 and a beta of 0.89. Quest Diagnostics has a twelve month low of $119.59 and a twelve month high of $152.00. The company has a quick ratio of 0.91, a current ratio of 1.00 and a debt-to-equity ratio of 0.57.
Wall Street Analyst Weigh In
DGX has been the topic of several analyst reports. StockNews.com raised shares of Quest Diagnostics from a “hold” rating to a “buy” rating in a research report on Tuesday, July 23rd. Piper Sandler upped their target price on Quest Diagnostics from $145.00 to $150.00 and gave the stock a “neutral” rating in a report on Monday, July 29th. Citigroup upgraded Quest Diagnostics from a “neutral” rating to a “buy” rating and raised their price target for the company from $145.00 to $165.00 in a research note on Wednesday, July 10th. Robert W. Baird upped their price objective on Quest Diagnostics from $153.00 to $154.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 24th. Finally, JPMorgan Chase & Co. raised their target price on shares of Quest Diagnostics from $152.00 to $155.00 and gave the company a “neutral” rating in a research note on Thursday, May 30th. Eight equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, Quest Diagnostics has an average rating of “Hold” and an average price target of $150.58.
Get Our Latest Research Report on DGX
Insider Activity
In related news, SVP Mark E. Delaney sold 420 shares of the business’s stock in a transaction on Wednesday, July 24th. The shares were sold at an average price of $143.08, for a total transaction of $60,093.60. Following the transaction, the senior vice president now owns 5,019 shares in the company, valued at approximately $718,118.52. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.79% of the stock is owned by company insiders.
Quest Diagnostics Company Profile
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.
Recommended Stories
- Five stocks we like better than Quest Diagnostics
- Breakout Stocks: What They Are and How to Identify Them
- Brinker International’s Price Dip is an Appetizing Entry Point
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- 3 Stocks That Could Beat the September Blues
- The Most Important Warren Buffett Stock for Investors: His Own
- Canopy Growth Stock: Can It Sustain Recent Gains?
Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.